Impact of Multidrug-resistant Pseudomonas aeruginosa Infection on Patient Outcomes

Elizabeth B Hirsch; Vincent H Tam


Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(4):441-451. 

In This Article

Five-year View

As the prevalence rate of multidrug resistance continues to rise and spread worldwide, more frequent outbreaks of MDR infection are anticipated. Crude hospital mortality of patients with infections (whether they can be attributed to multidrug resistance to a scientific certainty or not) is expected to increase. Unless new and effective antimicrobial agents are developed for clinical use in time, we are at risk of returning to the preantibiotic era. In such difficult times, there is an urgent need for the scientific/medical community to unite and devise effective treatment strategies, preferably via interdisciplinary collaborations.